Financial News
Articles published by Apellis Pharmaceuticals, Inc.
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
December 11, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 01, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
September 25, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
September 05, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Via GlobeNewswire
Tickers
APLS
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/74cdaef6-c648-4b12-83e0-b1b319081daa/small/apellis-logo-jpg.jpg)
Via GlobeNewswire
Tickers
APLS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.